Cel-Sci (NYSEAMERICAN:CVM) Announces Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) released its quarterly earnings data on Friday. The company reported ($0.47) earnings per share (EPS) for the quarter, FiscalAI reports.

Cel-Sci Price Performance

Shares of CVM traded up $0.05 during trading hours on Friday, hitting $1.54. The stock had a trading volume of 217,281 shares, compared to its average volume of 270,722. The stock has a market capitalization of $26.92 million, a price-to-earnings ratio of -0.16 and a beta of 0.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. The company’s fifty day moving average is $1.22 and its two-hundred day moving average is $2.71. Cel-Sci has a 52 week low of $0.89 and a 52 week high of $13.48.

Institutional Trading of Cel-Sci

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after buying an additional 109,352 shares in the last quarter. Geode Capital Management LLC grew its position in Cel-Sci by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after acquiring an additional 18,432 shares during the last quarter. Bank of America Corp DE grew its position in Cel-Sci by 2,188.2% during the 2nd quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after acquiring an additional 39,190 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Cel-Sci by 133.0% during the 1st quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after purchasing an additional 20,484 shares in the last quarter. Finally, State Street Corp increased its holdings in Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after purchasing an additional 2,300 shares in the last quarter. 12.08% of the stock is owned by institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.